A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant)

Inclusion Criteria: * Participants aged 18 years and above; * Have not received any influenza vaccine in the past six months and have no plan to receive other influenza vaccines during the trial period; * Have not had influenza in the past 6 months (confirmed by any clinical, serological, or microbiological method); * Able to obtain the participant's own informed consent; * The participant themselves can comply with the requirements of the clinical trial protocol. Exclusion Criteria: * Axillary temperature \> 37.0℃ on the day of enrollment; * Female participants of childbearing age with a positive urine pregnancy test result, or who are breastfeeding, or have a plan to have children within 12 months; * Those with a history of severe allergic diseases (such as anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrotic reaction), or who are allergic to any component of the test vaccine, such as eggs, gentamicin sulfate, formaldehyde, TritonX-100, etc.; * Those with clinically significant abnormal laboratory test results, which are determined by the researcher as unsuitable for vaccine vaccination； * Those who have had an acute illness, acute exacerbation of a chronic disease, or used antipyretic, analgesic, or anti-allergic drugs within the past 3 days; * Autoimmune diseases or immune deficiency, asplenia, functional asplenia, and asplenia or splenectomy caused by any condition; those who have received long-term systemic…